Compare LGL & OKYO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LGL | OKYO |
|---|---|---|
| Founded | 1917 | 2007 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 85.1M | 78.2M |
| IPO Year | 2017 | 2021 |
| Metric | LGL | OKYO |
|---|---|---|
| Price | $6.70 | $1.43 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $8.33 |
| AVG Volume (30 Days) | 7.3K | ★ 56.9K |
| Earning Date | 11-24-2026 | 07-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 37.50 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $4,169,000.00 | N/A |
| Revenue This Year | $89.49 | N/A |
| Revenue Next Year | $27.85 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.45 | $1.26 |
| 52 Week High | $7.88 | $3.20 |
| Indicator | LGL | OKYO |
|---|---|---|
| Relative Strength Index (RSI) | 53.55 | 48.86 |
| Support Level | $6.58 | N/A |
| Resistance Level | $7.33 | $1.71 |
| Average True Range (ATR) | 0.17 | 0.11 |
| MACD | 0.02 | -0.01 |
| Stochastic Oscillator | 77.55 | 50.98 |
LGL Group Inc is a holding company engaged in services, merchant investment, and manufacturing business activities. The company has two reportable segments: Electronic Instruments and Merchant Investment. The Electronic Instruments segment, which generates key revenue, is focused on designing and manufacturing high-performance Frequency and Time reference standards that form the basis for timing and synchronization in various applications, including satellite communication, time transfer systems, network synchronization, electricity distribution, and metrology. The Merchant Investment segment comprises various investment vehicles in which the company invests its capital.
OKYO Pharma Ltd is a clinical-stage ophthalmology company focused on developing differentiated therapies for corneal and anterior segment diseases. It is advancing a pipeline designed to improve outcomes for patients suffering from debilitating ocular diseases that impact vision and ocular comfort. The company's main program, urcosimod, is being developed as a potential treatment for neuropathic corneal pain. Additionally, its development pipeline includes an exploratory candidate, OK-201, a non-opioid analgesic drug candidate, as a potential drug to treat acute and chronic ocular pain. The company has only one operating segment: the research and development of biotechnological and pharmaceutical products.